咯萘啶

  • 网络Pyronaridine;Malaridine
咯萘啶咯萘啶
  1. 咯萘啶在血中呈不均一分布,im后1~96h,球/浆浓度比为3~6。

    Pyronaridine was not homogeneously distributed in the blood , the blood cell / plasma concentration ratios being 3 ~ 6 during 1 ~ 96 h after intramuscular dosing .

  2. 咯萘啶分别与甲氟喹等5种药物伍用的体外抗疟作用

    In vitro effect of pyronaridine combined with five antimalarials to Plasmodium falciparum

  3. RP-HPLC法测定磷酸咯萘啶注射液含量及有关物质

    RP-HPLC determination of malaridine phosphate injection and its related substances

  4. 磷酸咯萘啶新剂型的质量研究和稳定性研究;

    Test of quality and stability of new preparation .

  5. 恶性疟原虫对咯萘啶敏感性的体外微量测试方法

    Establishment of In vitro Microtest for Determining Sensitivity of Plasmodium falciparum to Pyronaridine

  6. 咯萘啶对雄性小鼠的显性致死试验

    Dominant lethal test with pyronaridine on male mice

  7. 抗疟药咯萘啶与磺胺多辛及乙胺嘧啶配伍治疗恶性疟结果的分析

    Analysis on results of antimalarial pyronaridine combined with sulfadoxine and pyrimethamine to falciparum malaria

  8. ~3H-咯萘啶在小鼠体内的分布和排泄

    Distribution and excretion of ~ 3h-pyronaridine in mice

  9. 咯萘啶最低有效浓度的测定及抗疟治疗剂量方案的探讨

    Determination of minimum effective concentration and proposed dosage regimen of pyronaridine for treatment of malaria

  10. 恶性疟原虫对咯萘啶/磺胺多辛/乙胺嘧啶敏感性体外测定方法的研究

    Studies on the sensitivity of Plasmodium falciparum to pyronaridine / sulfadoxine / pyrimethamine in vitro

  11. 氚标记抗疟药磷酸咯萘啶的研制

    Preparation of pyronaridine labelled with tritium

  12. 磷酸咯萘啶与磺胺多辛、伯喹伍用在抗氯喹地区治疗恶性疟的观察

    Combined use of pyronaridine , sulfadoxine and primaquine in areas with chloroquine - resistant falciparum malaria

  13. 咯萘啶针剂与防疟2号片及伯喹联用治疗恶性疟疾的效果

    Effects of combined use of pyronaridine injection and tablet No.2 malaria prophylaxis and primaquine on falciparum malaria

  14. 云南南部恶性疟原虫对氯喹、咯萘啶、青蒿琥酯、哌喹敏感性的体外测定

    Sensitivity in vitro of Plasmodium falciparum to chloroquine , pyronaridine , artesunate and piperaquine in South Yunnan

  15. 肿瘤多药耐药逆转剂&磷酸咯萘啶口服新剂型的研究

    The Study of a New Oral Preparation of Tumorous Multidrug - Resistance Inhibit Agent - Pyronaridine Phosphate

  16. 磷酸咯萘啶及其合并双氢青蒿素治疗疟疾效果观察

    Observation on efficacy of pyronaridine phosphate and it combined with dihydroartemisinin for treatment of malaria in eritrea , Africa

  17. 咯萘啶与磺胺多辛-乙胺嘧啶单剂及两天疗法加伯氨喹治疗恶性疟的效果

    Comparative studies on the treatment of drug resistant falciparum malaria with single dose or two day regimens of pyronaridine / sulfadoxine pyrimethamine plus primaquine

  18. [结论]恶性疟原虫对咯萘啶/磺胺多辛/乙胺嘧啶的敏感性可用体外微量法进行测定。

    [ Conclusion ] The in vitro method can be used to assess the sensitivity of P. falciparum to pyronaridine / sulfadoxine / pyrimethamine .

  19. 目的观察国产抗疟药磷酸咯萘啶单方和磷酸咯萘啶合并双氢青蒿素在厄利特里亚治疗疟疾的近期疗效。

    Objective To observe the short-term efficacy of the domestic anti-malaria drugs pyronaridine phosphate and pyronaridine phosphate combined with dihydroartemisinin for treatment of malaria in the state of eritrea .

  20. 结果:测定21例恶性疟患者对氯喹、哌喹、咯萘啶和青蒿琥酯的抗性率分别为85.7%、66.7%、38.1%和5.0%。

    RESULTS : The resistance rates of the malaria parasite to chloroquine , piperaquine pyronaridine and artesunate were 85 7 % , 66 7 % , 38 1 % and 5 0 % , respectively .

  21. 咯萘啶组治疗后平均转阴时间为59.3小时,平均退热时间为25.5小时,而氟喹组分别为60及28.1小时。

    All the patients treated with pyronaridine phosphate became free from parasite in an average of 59.3 hours and free from fever in 25.5 hours , while patients treated with chloroquine in 60 hrs and 28.1 hrs .

热门查询